Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.

Achhra, Amit C; Mocroft, Amanda; Ross, Michael; Ryom-Nielson, Lene; Avihingsanon, Anchalee; Bakowska, Elzbieta; Belloso, Waldo; Clarke, Amanda; Furrer, Hansjakob; Lucas, Gregory M; Ristola, Matti; Rassool, Mohammed; Ross, Jonathan; Somboonwit, Charurut; Sharma, Shweta; Wyatt, Christina (2017). Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. International journal of antimicrobial agents, 50(3), pp. 453-460. Elsevier 10.1016/j.ijantimicag.2017.04.021

[img]
Preview
Text
1-s2.0-S0924857917302303-main.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview
[img] Text
1-s2.0-S0924857917302303-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (916kB) | Request a copy

BACKGROUND Both untreated HIV infection and antiretroviral therapy (ART) have been associated with worsening kidney function. The impact of earlier ART initiation on kidney function has not been studied. METHODS The START trial was a randomized comparison of immediate versus deferred ART initiation among HIV+ persons with CD4+ counts >500 cells/mm(3). Serum creatinine and urine dipstick protein were measured at baseline, months 1, 4, 8, 12, and annually thereafter. We compared the two arms for changes in estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) over time using longitudinal mixed models. FINDINGS Of 4685 START participants, 4629 (n=2294 in immediate and 2335 in deferred arm) individuals were included. Median baseline CD4 and eGFR were 651 cells/mm(3) and 111⋅5 mL/min/1⋅73m(2). ART was initiated in 2271 participants (99%) in the immediate and 1127 participants (48%) in the deferred arm, accounting for over 94% and 19% of follow-up time, respectively. Overall, 89% started ART using a tenofovir-based regimen. Over a median follow-up of 2⋅1 years, the mean eGFR was 0⋅56 (95% CI: 0⋅003-1⋅11) mL/min/1⋅73m(2) higher in the immediate arm than the deferred arm. This difference was more prominent after adjustment for current use of tenofovir or boosted-protease inhibitors (1⋅85, 95% CI: 1⋅21-2⋅50), and was more prominent in participants of black race (30% overall) (3⋅90, 95% CI: 2⋅84-4⋅97) compared to non-black (1⋅05, 95% CI: 0⋅33-1⋅77) (p<0⋅001 for interaction). Relative risk for proteinuria in the immediate vs. deferred arm was 0⋅74 (95% CI: 0⋅55-1⋅00), P=0⋅049. The incidence of chronic kidney disease as defined by eGFR < 60 or dipstick proteinuria was low, and there was no significant difference between treatment arms (incidence rate ratio 0.79, 95% CI 0.59-1.05). CONCLUSION In the short-term, immediate ART initiation was associated with a modestly higher eGFR and lower risk of proteinuria as opposed to deferring ART- a difference more pronounced in those with black race. Whether this early benefit translates into a lower risk of chronic kidney disease requires further follow-up.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Furrer, Hansjakob

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0924-8579

Publisher:

Elsevier

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

07 Nov 2017 11:04

Last Modified:

01 Oct 2018 02:30

Publisher DOI:

10.1016/j.ijantimicag.2017.04.021

PubMed ID:

28668686

Uncontrolled Keywords:

CKD HAART HIV START eGFR kidney renal function

BORIS DOI:

10.7892/boris.101872

URI:

https://boris.unibe.ch/id/eprint/101872

Actions (login required)

Edit item Edit item
Provide Feedback